Aequus Pharmaceuticals (AQSZF)

[BioSpecialist]

AQS is very close to acquire rights up to 9 Marketed Products
with these Products aequus will have 11 Marketed Products so you can be sure that they will reach profitability very quickly . Now add Aequus other real Big drugs Oxcarbazepine XR ,Topiramate XR and AQS1301 which all three Drugs are expected to enter the Market by around mid 2018 with these Drugs revenue will explode to the upside i think peak sales for all the products mentioned above can hit $100 MILLION in revenue .Maybe now you guys understand why i say this goldmine with a dirt low market cap of US$15 million has 20 bagger potential and even that is conservative in the long term.


9 Products + Vististan + Tacrolimus = Peak Sales of $15 Million
Topiramate XR +Oxcarbazepine XR = Peak Sales of $40 Million
AQS1301 (AQS has global rights) = Peak Sales of minimum $50 million (USA alone)





Ceo Janzen is talking about these 4 drugs Topiramate XR Oxcarbazepine XR ,Vististan & Tacrolimus in the interview below
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada

Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.


AQS1301
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License (If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)

The Abilify brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.